/
IBIO
$1.73+$0.06 (+3.59%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$83.0M
50M shares
52-week range
$0.56 – $3.82
36% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.94%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-758.27
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $444.0K | $2.0M | $1.6M | $2.4M | $1.9M | $0 | $225.0K | $400.0K |
| Cost of revenue | $0 | $0 | $703.0K | $1.5M | $3.8M | $0 | $0 | $0 |
| Gross profit | $444.0K | $2.0M | $935.0K | $909.0K | −$1.9M | $0 | $225.0K | $400.0K |
| Gross margin | 100.0% | 100.0% | 57.1% | 38.3% | -101.2% | — | 100.0% | 100.0% |
| R&D | $4.0M | $5.5M | $3.6M | $10.0M | $9.8M | $10.3M | $5.2M | $8.3M |
| Operating income | −$14.2M | −$15.8M | −$14.0M | −$31.1M | −$29.7M | −$29.3M | −$16.6M | −$18.6M |
| EBITDA | −$12.5M | −$13.9M | −$11.7M | −$28.6M | −$25.7M | −$27.8M | −$14.0M | −$17.0M |
| Net income | −$16.1M | −$17.6M | −$16.4M | −$23.2M | −$50.4M | −$65.0M | −$24.9M | −$18.4M |
| Net margin | -3627.3% | -871.8% | -1003.6% | -978.8% | -2674.7% | — | -11069.8% | -4594.3% |
| EPS (diluted) | -770.00 | -471.65 | -304.64 | -59.98 | -2889.06 | -106.18 | -6.50 | -1.75 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $157143 | $-0.33 | $-0.43–$-0.30 | 5 |
| 2027 | $85714 | $-0.31 | $-0.35–$-0.26 | 5 |
| 2028 | $125000 | $-0.40 | $-0.43–$-0.37 | 2 |
| 2029 | $250000 | $-0.68 | $-1.14–$-0.60 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.24
Price
$1.73
Implied downside
-86%
Peer comparison
iBio, Inc. Common Stock
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
www.ibioinc.com- Employees
- 20
- IPO / List date
- Aug 19, 2008
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds IBIO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 353,339 | $681.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-11-29 | 1-for-20reverse |
| 2022-10-10 | 1-for-25reverse |
| 2018-06-11 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded IBIO yet.
